Partnerships

Seeking Strategic Partners

Sementis is interested in forming strategic partnerships with the following groups

Large vaccine companies

Primarily large Pharmaceutical companies which already have their own vaccine capabilities. These KSPs have:

  • Knowledge and direct experience in Vaccines
  • Market access and sales channels (including vaccine specific)
  • Products that may be disrupted or enhanced by the SCV platform

Emerging vaccine companies

Companies that specialise in developing Biotech Vaccines. These KSPs have:

  • Knowledge and experience in the Vaccine sector
  • Market access pathways and sales channels
  • Products that may be disrupted or enhanced by the SCV platform

Large Pharmaceutical Companies

Large Pharmaceutical companies which currently either don’t have a vaccine program or do not currently have immunotherapeutic vaccine capabilities. These KSPs have:

  • Knowledge and experience in the broader Pharmaceutical space
  • Market access pathways and sales channels
  • Strategic potential for the integration of the SCV platform to their wider business

Global CDMO Companies

Companies that provide services to other pharmaceutical businesses on a contract basis. These KSPs have:

  • Knowledge and experience in the broader pharmaceutical space and are potentially vaccine specific
  • Services that may be disrupted or enhanced by the SCV platform

Veterinary vaccine companies

Companies that specialise in developing vaccines intended for use in animals. These KSPs have:

  • Knowledge and experience in the animal vaccine sector
  • Market access pathways and sales channels for animal vaccines

Defence

Primarily defence programs that deal with biological countermeasures. These KSPs have:

  • Understanding of potential technology applicability outside of medical sector
  • Market access pathways (primarily through government channels)

Not for Profit

Vaccine companies or NGOs whose work is based primarily in the developing world. These KSPs have:

  • Knowledge and experience in the Vaccine sector
  • Market access pathways and sales channels (developing world)
  • Products that may be disrupted or enhanced by the SCV platform

Academia

Academic institutions with interest in discovering and developing new drug products. These KSPs have:

  • Interest to engage industry partners for research and discovery purposes
  • Access to funding restricted for academic institutionsÂ